SCHEMBL4480649

SCHEMBL4480649

COc1ccccc1CNS(=O)(=O)c1cccc2c(O)cccc12

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
KDM4E B2RXH2 1/20 0.51
POLB P06746 1/20 0.51
HTT P42858 1/20 0.51
LMNA P02545 3/20 0.50
GAA P10253 1/20 0.50
FABP4 P15090 2/20 0.49
ALDH1A1 P00352 1/20 0.48
MAPK1 P28482 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
NAMPT P43490 1/20 0.47
TP53 P04637 1/20 0.47
MAPT P10636 1/20 0.47
NSD2 O96028 1/20 0.46
TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4489171 0.90 LMNA (0.51) MEN1KMT2ALMNAGAAFABP4
SCHEMBL4446562 0.85 NSD2 (0.65) MEN1KMT2AKDM4EPOLBHTT
Hydrochloric Acid SCHEMBL4448775 0.84 NSD2 (0.65) MEN1KMT2ALMNANSD2
SCHEMBL4492415 0.83 ALDH1A1 (0.55) MEN1KMT2AKDM4EGAAALDH1A1
SCHEMBL4452477 0.82 MEN1 (0.48) MEN1KMT2AKDM4EPOLBHTT
SCHEMBL4487513 0.82 CA2 (0.60) KDM4EHTTALDH1A1NSD2
SCHEMBL4492967 0.78 KMT2A (0.51) MEN1KMT2AKDM4EPOLBHTT
SCHEMBL4483058 0.78 NPY1R (0.49) MEN1KMT2AKDM4EHTTNAMPT
SCHEMBL4492975 0.78 NSD2 (0.58) MEN1KMT2APOLBLMNAFABP4
SCHEMBL4483905 0.77 NSD2 (0.69) KDM4EALDH1A1MAPK1NSD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598418-B2 Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-10-06 US claimed
US-20050215645-A1 Amide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2005-09-29 US claimed
US-7598418-B2 Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-10-06 US disclosed
US-20050215645-A1 Amide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215645-A1 Amide derivatives OGG1, HDAC1, BCL2A1 MEN1 4507/4885KMT2A 1012/4885KDM4E 2212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.